검색어: darifenacin (덴마크어 - 영어)

aktivt stof: darifenacin.
the active substance is darifenacin.

emselex 15 mg depottabletter darifenacin
emselex 15 mg prolonged-release tablets darifenacin

darifenacin udskilles i mælk hos rotter.
darifenacin is excreted in the milk of rats.

effekt af andre lægemidler på darifenacin
effects of other medicinal products on darifenacin

darifenacin metaboliseres af cyp3a4 og cyp2d6.
darifenacin is metabolised by cyp3a4 and cyp2d6.

- aktivt stof: darifenacin (som hydrobromid).
- the active substance is darifenacin (as hydrobromide).

amning darifenacin udskilles i mælk hos rotter.
lactation darifenacin is excreted into the milk of rats.

emselex 15 mg depottabletter darifenacin (som hydrobromid)
emselex 15 mg prolonged-release tablets darifenacin (as hydrobromide)

darifenacin er en moderat hæmmer af enzymet cyp2d6.
darifenacin is a moderate inhibitor of the enzyme cyp2d6.

hver tablet indeholder 15 mg darifenacin (som hydrobromid)
each tablet contains 15 mg of darifenacin (as hydrobromide)

hver tablet indeholder 15 mg darifenacin (som hydrobromid).
each tablet contains 15 mg darifenacin (as hydrobromide).

børn der er ikke foretaget farmakokinetiske undersøgelser med darifenacin hos børn.
paediatric patients the pharmacokinetics of darifenacin have not been established in the paediatric population.

det aktive stof i emselex, darifenacin, er et antikolinergt middel.
the active substance in emselex, darifenacin, is an anticholinergic medicine.

graviditet der er ikke udført forsøg med darifenacin hos gravide kvinder.
pregnancy there are no studies of darifenacin in pregnant women.

33% for 20 mg paroxetin ved en dosering på 30 mg darifenacin).
concomitant treatment with potent cyp2d6 inhibitors results in an increase in exposure (e. g. of 33% with 20 mg paroxetine at the 30 mg dose of darifenacin).

darifenacin er en selektiv muskarin m3 receptorantagonist (m3 sra) in vitro.
darifenacin is a selective muscarinic m3 receptor antagonist (m3 sra) in vitro.

behandling med darifenacin resulterede i en lettere øget eksponering af cyp3a4 substratet midazolam.
darifenacin treatment resulted in a modest increase in the exposure of the cyp3a4 substrate midazolam.

kun en lille procentdel af den udskilte mængde var uomdannet darifenacin (3%).
only a small percentage of the excreted dose was unchanged darifenacin (3%).

cyp3a4 substrater behandling med darifenacin resulterede i en lettere øget eksponering af cyp3a4 substratet midazolam.
cyp3a4 substrates darifenacin treatment resulted in a modest increase in the exposure of the cyp3a4 substrate midazolam.

den øgede digoxin eksponering kan skyldes konkurrence mellem darifenacin og digoxin om p-glycoprotein.
the increase in digoxin exposure could be caused by competition between darifenacin and digoxin for p-glycoprotein.